Loading...
XSHG600789
Market cap1.29bUSD
Jan 09, Last price  
10.53CNY
1D
-10.00%
1Q
37.11%
Jan 2017
40.96%
Name

Shandong Lukang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600789 chart
P/E
38.44
P/S
1.55
EPS
0.27
Div Yield, %
1.52%
Shrs. gr., 5y
1.07%
Rev. gr., 5y
12.85%
Revenues
6.09b
+8.39%
1,027,521,6401,155,936,1501,113,639,9661,462,410,5681,789,441,9781,985,116,9922,196,144,6322,332,872,9562,339,454,2612,210,685,3422,312,103,1372,410,287,7152,505,591,8952,599,288,8813,329,604,7873,732,718,8824,205,109,0974,890,672,6085,621,441,9036,092,960,626
Net income
246m
+78.37%
04,976,569025,973,64535,205,21237,579,648129,611,33315,013,068010,857,94307,897,23129,102,001114,236,705161,386,660121,251,309227,876,51689,098,691138,013,129246,171,797
CFO
604m
+35.92%
63,242,043161,637,59756,244,212137,295,792209,387,241199,492,194308,883,167123,285,170115,202,032256,497,339108,564,46978,385,703296,231,759275,509,822351,086,185361,866,734234,552,377149,325,527444,377,008604,005,701
Dividend
Jun 21, 20240.09 CNY/sh
Earnings
Apr 23, 2025

Profile

Shandong Lukang Pharmaceutical Co.,Ltd. manufactures and sells bio-pharmaceuticals and antibiotics in China. The company offers human and animal active pharmaceutical ingredients; human and animal preparations; bio-pesticides; herbal medicines; and amino acid. It is also involved in the sewage treatment, odor control, sewage facilities management, environmental protection material production and sale, and management of water disposal. The company exports its products to approximately 40 countries in Asia, Europe, Africa, and the United States. The company was formerly known as Jining Antibiotic Factory and changed its name to Shandong Lukang Pharmaceutical Co.,Ltd. in October 1993. Shandong Lukang Pharmaceutical Co.,Ltd. was founded in 1966 and is based in Jining, China.
URL
https://www.lkpc.com/
IPO date
Feb 26, 1997
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,092,961
8.39%
5,621,442
14.94%
Cost of revenue
5,507,749
5,169,011
Unusual Expense (Income)
NOPBT
585,212
452,431
NOPBT Margin
9.60%
8.05%
Operating Taxes
16,188
6,980
Tax Rate
2.77%
1.54%
NOPAT
569,024
445,451
Net income
246,172
78.37%
138,013
54.90%
Dividends
(143,728)
(44,110)
Dividend yield
2.25%
0.66%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,102,497
1,986,404
Long-term debt
1,308,926
868,744
Deferred revenue
110,969
100,406
Other long-term liabilities
123,858
123,858
Net debt
1,282,515
2,076,495
Cash flow
Cash from operating activities
604,006
444,377
CAPEX
(337,914)
Cash from investing activities
Cash from financing activities
(93,923)
FCF
965,519
245,546
Balance
Cash
799,653
690,070
Long term investments
329,255
88,583
Excess cash
824,260
497,581
Stockholders' equity
1,893,848
2,306,364
Invested Capital
5,563,337
6,052,525
ROIC
9.80%
7.47%
ROCE
9.16%
6.91%
EV
Common stock shares outstanding
896,037
920,088
Price
7.14
-1.65%
7.26
-3.07%
Market cap
6,397,707
-4.22%
6,679,835
1.28%
EV
7,809,875
8,906,643
EBITDA
966,338
800,554
EV/EBITDA
8.08
11.13
Interest
79,175
98,043
Interest/NOPBT
13.53%
21.67%